Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: GlaxoSmithKline 2Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: GlaxoSmithKline 2Q11

Avandia, Valtrex and pandemic losses reduce revenues

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

GSK 2Q

2Q Revenues: GBP 6.7 billion (-4%)

2Q Earnings: GBP 1.1 billion (loss of GBP 252 million in 2Q10)

YTD Revenues: GBP 13.3 billion (-7%)

YTD Earnings: GBP 2.7 billion (+139%)

All results in GBP, not dollars.

Comments: Pharmaceuticals and Vaccines revenues fell 3% to GBP 5.4 billion in 2Q11, as a result of Avandia and Valtrex losses, in concert with reduced pandemic sales compared to 2010. YTD revenues fell 9% to GBP 10.7 billion. Pharma/Vaccine sales in the U.S. were down 4% for 2Q and 8% for YTD; those sales in Europe were down 9% and 17% for the two periods, respectively; in Emerging Markets, they were up 12% and 5% for the two periods. Pharmaceutical revenues were led by Seretide/Advair, at GBP 1.3 billion (+2%) for 2Q and GBP 3.6 billion (+3%) YTD. Valtrex revenues, impacted by generics, dropped 48% to GBP 86 million in 2Q. Restructuring efforts have overachieved and GSK has revised the savings from this effort to GBP 2.5 billion from 2.2 billion. The company will ” continue to apply sustained pressure to GSK’s cost base to realize further savings, through improvements in areas such as support functions, supply chain and procurement efficiency.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics